No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
PSTV Plus Therapeutics
- 1.9300
- -0.0700-3.50%
Close Jun 18 16:00 ET
- 1.9500
- +0.0200+1.04%
Post 16:27 ET
11.01MMarket Cap-660P/E (TTM)
2.0300High1.8300Low69.15KVolume2.0300Open2.0000Pre Close131.23KTurnover1.38%Turnover RatioLossP/E (Static)5.70MShares3.210052wk High-2.28P/B9.69MFloat Cap0.969452wk Low--Dividend TTM5.02MShs Float7507.4985Historical High--Div YieldTTM10.00%Amplitude0.9690Historical Low1.8970Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Plus Therapeutics to Receive $3.3 Million Advance Payment From CPRIT For Radiotherapeutic Development Program
Plus Therapeutics (PSTV) said Friday it received notice of a $3.3 million advance payment from the Cancer Prevention & Research Institute of Texas, or CPRIT, as part of a $17.6 million grant awarded i
Express News | PLUS THERAPEUTICS Says Greg Fuller Joins Company As Vice President Of Medical Affairs And Medical Director; Reports $3.3M Advance Payment From CPRIT
Express News | Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment From Cprit
Express News | Aigh Capital Management, LLC Reports Passive Stake of 9.9% in Plus Therapeutics Inc as of May 9, 2024- SEC Filing
Express News | Plus Therapeutics Inc - on May 31, Drew $3.3 Mln on Its Existing Margin Loan Facility With Pershing LLC
Buy Rating Affirmed for Plus Therapeutics on Strong Clinical Progress and Robust Financial Health
Comments
$Plus Therapeutics(PSTV.US$ Plus Therapeutics (PSTV) said Friday it received notice of a $3.3 million advance payment from the Cancer Prevention & Research Institute of Texas, or CPRIT, as part of a $17.6 million grant awarded in September 2022.
The company said the funding will support the leptomeningeal cancer radiotherapeutic development program and CNSide testing in the ReSPECT-LM trial.
The company said the funding will support the leptomeningeal cancer radiotherapeutic development program and CNSide testing in the ReSPECT-LM trial.
1
$Plus Therapeutics(PSTV.US$ Plus Therapeutics (NASDAQ:PSTV) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(1.09) by 31.19 percent. This is a 63.77 percent increase over losses of $(2.07) per share from the same period last year. The company reported quarterly sales of $1.677 million which missed the analyst consensus estimate of $1.688 million by 0.62 percent. This is a 231.42 percent increase over sales of $506.000 thousand the same period last ye...
1
2
$Plus Therapeutics(PSTV.US$
NEWS
Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial
Positive Acquisition of CNSide™ diagnostic platform to enhance LM diagnostic accuracy. Successful presentation of topline data from the FORESEE trial meeting primary endpoint. Potential partnering opportunities for CNSide™ to expand market size. Expected attractive near-term return on investment for stockholders. Negative Cur...
NEWS
Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial
Positive Acquisition of CNSide™ diagnostic platform to enhance LM diagnostic accuracy. Successful presentation of topline data from the FORESEE trial meeting primary endpoint. Potential partnering opportunities for CNSide™ to expand market size. Expected attractive near-term return on investment for stockholders. Negative Cur...
$Plus Therapeutics(PSTV.US$
NEWS
Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial
Plus Therapeutics, Inc. (Nasdaq: PSTV) will host an investor call on May 9th, 2024, to discuss the acquisition of CNSide assets and provide updates on the FORESEE clinical trial. The company aims to leverage the acquired assets for CNS cancers and share key insights with investors.
Positive
Strategic acquisition of C...
NEWS
Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial
Plus Therapeutics, Inc. (Nasdaq: PSTV) will host an investor call on May 9th, 2024, to discuss the acquisition of CNSide assets and provide updates on the FORESEE clinical trial. The company aims to leverage the acquired assets for CNS cancers and share key insights with investors.
Positive
Strategic acquisition of C...
Plus Therapeutics Secures Up to $18 Million Through Strategic Private Financing.
To bolster its financial position and further its research in targeted radiotherapeutics, Plus Therapeutics, Inc. (Nasdaq: PSTV), based out of Austin, Texas, has announced a substantial private placement financing agreement. The deal, set to raise up to approximately $18 million in gross proceeds, has been orchestrated with the support of ne...
To bolster its financial position and further its research in targeted radiotherapeutics, Plus Therapeutics, Inc. (Nasdaq: PSTV), based out of Austin, Texas, has announced a substantial private placement financing agreement. The deal, set to raise up to approximately $18 million in gross proceeds, has been orchestrated with the support of ne...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
RideTheTide : Good news, why stock is down instead?